ReviewNature reviews. Rheumatology2011
Pharmacogenetics: implications for therapy in rheumatic diseases.
Review in Nature reviews. Rheumatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07388407 (Pharmacogenetics of Leflunomide in the RA Management), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacogenetics of Leflunomide in the RA Management
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Efficacy and safety of mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases: a systematic review and meta-analysis of randomized controlled trials.Stem cell research & therapy · 2025Pooled it
- The genetic puzzle of rheumatoid arthritis: Causes, progression, and treatment.Biochemistry and biophysics reports · 2025Review
- Single-cell multi-dimensional data analysis decodes RNF19A-mediated drug resistance in rheumatoid arthritis fibroblast-like synoviocytes: mechanisms and biological insights.Cellular and molecular life sciences : CMLS · 2025Article
- Frequency of pharmacogenomic variants affecting safety and efficacy of immunomodulators and biologics in a South Asian population from Sri Lanka.Human genomics · 2024Article
- Different modalities to manage rheumatoid arthritis: an A to Z story.Future science OA · 2024Review
- Population Pharmacokinetics of Hydroxychloroquine and 3 Metabolites in COVID-19 Patients and Pharmacokinetic/Pharmacodynamic Application.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine.Pharmacogenomics and personalized medicine · 2020Review
- ADAM17 Genetic Variants and the Response of TNF-α Inhibitor in Rheumatoid Arthritis Patients.Pharmacogenomics and personalized medicine · 2020Article
- Gene expression analysis of vascular pathophysiology related to anti-TNF treatment in rheumatoid arthritis.Arthritis research & therapy · 2019Article
- Neuraxial Cytokines in Pain States.Frontiers in immunology · 2019Review
- IRAK2 is associated with susceptibility to rheumatoid arthritis.Clinical rheumatology · 2018Article
- HInflammopharmacology · 2018Article
- Effect of Fcγ-receptor 3a (RMD open · 2017Article
- Interleukin-6 promoter haplotypes are associated with etanercept response in patients with rheumatoid arthritis.Clinical rheumatology · 2015Article
- Development and validation of a clinical HPLC method for the quantification of hydroxychloroquine and its metabolites in whole blood.Future science OA · 2015Article
- Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.Inflammopharmacology · 2015Review
- Pharmacogenetics of treatment response in psoriatic arthritis.Current rheumatology reports · 2015Review
- Corrigendum: pharmacogenetics: implications for therapy in rheumatic diseases.Nature reviews. Rheumatology · 2015Article
- Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study.Pediatric rheumatology online journal · 2015Observational
- Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation.The Journal of clinical investigation · 2014Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DMARDs not only improve the joint pain and swelling associated with rheumatoid arthritis (RA), but also slow down the joint damage associated with the disease. The efficacy of biologic therapies, introduced in the past decade for the treatment of RA, has been unequivocally established. Similarly, in addition to traditional drugs such as hydroxychloroquine, new biologic agents such as rituximab have been introduced for systemic lupus erythematosus in recent years. However, considerable variability occurs in the responses of patients to these therapies. Pharmacogenetics, the study of variations in genes encoding drug transporters, drug-metabolizing enzymes and drug targets, and their translation to differential responses to drugs, is a rapidly progressing field in rheumatology. Pharmacogenetic applications, particularly to the old vanguard DMARD, methotrexate, and the newer, more expensive biologic agents, might make personalized therapy in rheumatic diseases possible. The pharmacogenetics of commonly used DMARDs and of biologic therapies are described in this Review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.